FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2475036292> ?p ?o ?g. }

• W2475036292 endingPage "12417" @default.
• W2475036292 startingPage "12408" @default.
• W2475036292 abstract "BRAF inhibitor vemurafenib achieves high response rate and an improvement in survival in patients with BRAF-mutated metastatic melanoma. However, median progression-free survival is only 6.9 months in the phase 3 study. Retrospective analyses suggest that treatment with BRAF inhibitors beyond initial progression might be associated with improved overall survival. We aimed to prospectively investigate the activity of prolonged treatment with vemurafenib and the addition of fotemustine in patients with systemic progression on prior single-agent BRAF inhibitor.In this two-centres, single-arm Phase 2 trial, we enrolled patients with systemic progressive disease during single-agent vemurafenib treatment. Participants received vemurafenib 960 mg twice daily or dose administered at time of disease progression with vemurafenib previous treatment and fotemustine 100 mg/m2 intravenously every three weeks. The primary endpoint was PFS.Thirty-one patients were enrolled in the study; 16 patients had brain metastases at baseline. Median PFS was 3.9 months and 19 patients (61.3%) achieved disease control (1 CR, 4 PR, 14 SD). For patients achieving disease control, median duration of treatment was 6 months. Median OS was 5.8 months from enrolment and 15.4 months from start of previous vemurafenib. Five patients (16.1%) had a G3-4 AE, the most common being thrombocytopenia, which occurred in 3 patients.This trial is registered with ClinicalTrials.gov number NCT01983124.The combination of vemurafenib plus fotemustine has clinical activity and an acceptable safety profile in BRAF-refractory patients." @default.
• W2475036292 created "2016-07-22" @default.
• W2475036292 creator A5000391768 @default.
• W2475036292 creator A5011850347 @default.
• W2475036292 creator A5020137513 @default.
• W2475036292 creator A5020665808 @default.
• W2475036292 creator A5026665975 @default.
• W2475036292 creator A5029398339 @default.
• W2475036292 creator A5039984848 @default.
• W2475036292 creator A5040419545 @default.
• W2475036292 creator A5050378759 @default.
• W2475036292 creator A5057849200 @default.
• W2475036292 creator A5060409280 @default.
• W2475036292 creator A5071929183 @default.
• W2475036292 creator A5072335274 @default.
• W2475036292 creator A5086592438 @default.
• W2475036292 date "2016-07-13" @default.
• W2475036292 modified "2023-10-18" @default.
• W2475036292 title "Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib" @default.
• W2475036292 cites W1481044359 @default.
• W2475036292 cites W1508281037 @default.
• W2475036292 cites W1534815147 @default.
• W2475036292 cites W1557490668 @default.
• W2475036292 cites W1576116802 @default.
• W2475036292 cites W1855435678 @default.
• W2475036292 cites W1965370740 @default.
• W2475036292 cites W1965480120 @default.
• W2475036292 cites W1982291583 @default.
• W2475036292 cites W1982326378 @default.
• W2475036292 cites W1997834281 @default.
• W2475036292 cites W2025130458 @default.
• W2475036292 cites W2065438964 @default.
• W2475036292 cites W2071668988 @default.
• W2475036292 cites W2096387850 @default.
• W2475036292 cites W2106543129 @default.
• W2475036292 cites W2109387929 @default.
• W2475036292 cites W2112121482 @default.
• W2475036292 cites W2114847324 @default.
• W2475036292 cites W2116978375 @default.
• W2475036292 cites W2121545342 @default.
• W2475036292 cites W2128542677 @default.
• W2475036292 cites W2137723371 @default.
• W2475036292 cites W2139707889 @default.
• W2475036292 cites W2144096834 @default.
• W2475036292 cites W2149642154 @default.
• W2475036292 cites W2160766792 @default.
• W2475036292 cites W2163188200 @default.
• W2475036292 cites W2163563579 @default.
• W2475036292 cites W2166262263 @default.
• W2475036292 cites W2170669390 @default.
• W2475036292 cites W2572174216 @default.
• W2475036292 doi "https://doi.org/10.18632/oncotarget.10589" @default.
• W2475036292 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5844757" @default.
• W2475036292 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29552321" @default.
• W2475036292 hasPublicationYear "2016" @default.
• W2475036292 type Work @default.
• W2475036292 sameAs 2475036292 @default.
• W2475036292 citedByCount "11" @default.
• W2475036292 countsByYear W24750362922017 @default.
• W2475036292 countsByYear W24750362922018 @default.
• W2475036292 countsByYear W24750362922019 @default.
• W2475036292 countsByYear W24750362922020 @default.
• W2475036292 countsByYear W24750362922021 @default.
• W2475036292 crossrefType "journal-article" @default.
• W2475036292 hasAuthorship W2475036292A5000391768 @default.
• W2475036292 hasAuthorship W2475036292A5011850347 @default.
• W2475036292 hasAuthorship W2475036292A5020137513 @default.
• W2475036292 hasAuthorship W2475036292A5020665808 @default.
• W2475036292 hasAuthorship W2475036292A5026665975 @default.
• W2475036292 hasAuthorship W2475036292A5029398339 @default.
• W2475036292 hasAuthorship W2475036292A5039984848 @default.
• W2475036292 hasAuthorship W2475036292A5040419545 @default.
• W2475036292 hasAuthorship W2475036292A5050378759 @default.
• W2475036292 hasAuthorship W2475036292A5057849200 @default.
• W2475036292 hasAuthorship W2475036292A5060409280 @default.
• W2475036292 hasAuthorship W2475036292A5071929183 @default.
• W2475036292 hasAuthorship W2475036292A5072335274 @default.
• W2475036292 hasAuthorship W2475036292A5086592438 @default.
• W2475036292 hasBestOaLocation W24750362921 @default.
• W2475036292 hasConcept C121332964 @default.
• W2475036292 hasConcept C121608353 @default.
• W2475036292 hasConcept C126322002 @default.
• W2475036292 hasConcept C142424586 @default.
• W2475036292 hasConcept C143998085 @default.
• W2475036292 hasConcept C203092338 @default.
• W2475036292 hasConcept C2776131300 @default.
• W2475036292 hasConcept C2776694085 @default.
• W2475036292 hasConcept C2777658100 @default.
• W2475036292 hasConcept C2780739268 @default.
• W2475036292 hasConcept C2994587330 @default.
• W2475036292 hasConcept C31760486 @default.
• W2475036292 hasConcept C502942594 @default.
• W2475036292 hasConcept C535046627 @default.
• W2475036292 hasConcept C71924100 @default.
• W2475036292 hasConcept C87355193 @default.
• W2475036292 hasConcept C90924648 @default.
• W2475036292 hasConceptScore W2475036292C121332964 @default.
• W2475036292 hasConceptScore W2475036292C121608353 @default.

• next